FDA Approves Keytruda (Pembrolizumab) for Head and Neck Cancer
By Stacy SimonThe US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) to treat people with head and neck squamous cell carcinoma that has spread or come back after previous chemotherapy treatment. It’s the first immunotherapy drug approved for head and neck cancer. Keytruda is already approved for melanoma and non-small cell lung cancer.The FDA based its approval on a clinical trial of 174 people with head and neck squamous cell carcinoma that had spread or come back after they were treated with platinum-based chemotherapy. Tumors shrank or disappeared in 16% of the participants who were given Keytruda. The improvement lasted for 6 months or longer in 82% of the people who responded.“Head and neck cancer is a complex disease that historically has been associated with high recurrence rates and poor long-term outcomes, highlighting the critical need for new treatment options,” said Dr. Tanguy Seiwert, associate director of the Head and Neck Cancer Program and assistant professor of medicine at The University of Chicago, in a statement. “The approval of Keytruda for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma is an important step forward in treating this disease.”The FDA acted under its accelerated approval program for drugs that show early promise against a serious disease. The company that makes the drug must submit additional clinical information after approval to demonstr...
Source: American Cancer Society :: News and Features - Category: Cancer & Oncology Tags: Oral Cavity and Oropharyngeal Cancer Source Type: news
More News: Back Pain | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Colon Cancer | Colorectal Cancer | Constipation | Cough | Food and Drug Administration (FDA) | Head and Neck Cancer | Hepatocellular Carcinoma | HNSCC | Hormones | Immunotherapy | Itchiness | Liver | Liver Cancer | Lung Cancer | Melanoma | Merck | Non-Small Cell Lung Cancer | Oral Cancer | Oral Cavity Cancer | Oropharyngeal Cancer | Pain | Skin | Skin Cancer | Squamous Cell Carcinoma | Urology & Nephrology